NCT00251992已完成3 期
Supportive Test for Acid-Related Symptoms (STARS II) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Uninvestigated Subjects With Upper Gastrointestinal Symptoms.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 1,200
- 试验地点
- 181
- 主要终点
- The primary outcome is whether the patient is a responder or not after 8 weeks treatment.
研究概览
简要总结
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 3 months of symptoms of pain or burning centered in the upper abdomen prior to enrollment.
- •Helicobacter pylori test performed at enrollment must be negative (Helicobacter pylori is a bacterial infection of the stomach).
排除标准
- •Patients with symptoms of other gastrointestinal diseases, such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD).
- •Helicobacter pylori eradication treatment during the last 12 months prior to enrollment.
结局指标
主要结局
The primary outcome is whether the patient is a responder or not after 8 weeks treatment.
The primary efficacy outcome is based on symptom score recorded daily during the study in a patient diary.
The patient will judge their symptoms of pain or burning centered in the upper abdomen on a four-graded scale (none, mild, moderate or severe).
次要结局
- The secondary efficacy outcomes are whether the patient is a responder or not after 4 weeks,
- The average symptom score and the percentage of symptom-free days during the 7-week treatment period,
- Presence/absence of specific GI symptoms after 4 and 8 weeks of therapy
研究者
研究点 (181)
Loading locations...
相似试验
已完成
3 期
Nexium Dyspepsia/ASTGastrointestinal DiseaseSigns and Symptoms, DigestiveDyspepsiaNCT00251914AstraZeneca1,500
已完成
不适用
A New Method for Determining Gastric Acid Output Using a Wireless CapsuleGastric Acid Secretory DisordersNCT00702533National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)80
已完成
4 期
Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor TreatmentHeartburnNCT02708355Pfizer55
已完成
不适用
Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy VolunteersPharmacodynamicNCT01237353University of California, San Francisco6
尚未招募
4 期
Evaluation of abdominal symptoms and gastrointestinal mucosal injuries in patients receiving oral anticoagulant dabigatrapper gastrointestinal mucosal injuryJPRN-UMIN000006344Kobe University Hospital50